id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
256262,2ff7780b-7fb2-4698-8e8a-e03df0e6827e,YY,MEDICAL ADVOCACY SERVICES,24772,AMERICAN COLLEGE OF RHEUMATOLOGY,2003,year_end,MMM,"CMS's rulemaking on the Medicare fee schedule.
CMS's effort to reform the AWP Methodology for Part B covered drugs.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2004-02-05T00:00:00-05:00
256263,2ff7780b-7fb2-4698-8e8a-e03df0e6827e,YY,MEDICAL ADVOCACY SERVICES,24772,AMERICAN COLLEGE OF RHEUMATOLOGY,2003,year_end,HCR,"Appropriations for Veterans Administration,AHRQ,NIH,CDC.
Issues related to proposed reform of the A.W.P. drug pricing methodology.
S.1/H.R.1 - Prescription Drug and Medicare Act of 2003.
S.11 - Patients First Act of 2003","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2004-02-05T00:00:00-05:00